DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

Key Takeaways DOCS grew FY25 revenues 20% to $570.4M and saw free cash flow jump 56%, but guidance lagged expectations. IRTC raised FY25 revenue outlook to $690-$700M following strong growth and key AI-driven clinical validation. IRTC stock soared 61.4% YTD, outpacing DOCS at 6.9%, fueled by innovation in diagnostics and margin gains.As digital health continues to evolve rapidly, Doximity (DOCS) and iRhythm Technologies (IRTC) stand out as two of the most intriguing players in AI-powered healthcare. Doxim ...